PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

Gain expert perspectives on the current and future use of PARP inhibitors in metastatic breast cancer with this online program, which features an on-demand Webcast capturing a dynamic CCO symposium at SABCS 2018, downloadable slides from the symposium, and expert-authored commentaries. 
Judy E. Garber, MD, MPH
Jennifer K. Litton, MD
Mark E. Robson, MD
Lee Schwartzberg, MD, FACP

Downloadable Slidesets

Download this slideset from a live symposium reviewing the mechanisms of action and resistance of PARP inhibitors used in cancer treatment.

Judy E. Garber, MD, MPH Jennifer K. Litton, MD Released: December 6, 2018

Download this slideset from a live symposium reviewing the current evidence for PARP inhibitors in MBC along with expert recommendations for their implementation in patient care.

Mark E. Robson, MD Lee Schwartzberg, MD, FACP Released: December 6, 2018

Download this slideset from a live symposium providing insights into new directions with PARP inhibitors for patients with breast cancer.

Jennifer K. Litton, MD Lee Schwartzberg, MD, FACP Released: December 6, 2018
Jointly provided by National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC
NCCN Logo

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by educational grants from
AstraZeneca
Pfizer Inc.
Tesaro

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue